Please login to the form below
Provention Bio
This page shows the latest Provention Bio news and features for those working in and with pharma, biotech and healthcare.
FDA rejects Provention Bio’s type 1 diabetes prevention drug
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) denying approval for Provention Bio’s type 1 diabetes (T1D) prevention drug teplizumab. ... goal,” said Ashleigh Palmer, co-founder and chief executive officer of
Latest news
-
FDA panel backs Provention Bio’s type 1 prevention drug teplizumab
On top of that, Provention Bio also submitted safety data for teplizumab in another indication, with the panelists commenting this could not be used to make a good comparison. ... Nevertheless, the Provention Bio’s chief executive oficer Ashleigh
-
Provention Bio wins PRIME designation for type 1 diabetes prevention drug
Meanwhile J&J partnered Crohn's drug flops in phase 2. Provention Bio has announced its lead candidate PRV-031 (teplizumab) has been granted Priority Medicines (PRIME) designation from the European ... We are very pleased the EMA recognises the
-
Tiziana joins type 1 diabetes prevention field
Cites potential advantages. Biopharma investors were recently wowed by data from a pipeline drug from Provention Bio which could delay the onset of type 1 diabetes in at-risk patients – and ... The share price of Provention Bio doubled last month
-
Type 1 diabetes prevention promise sends Provention Bio soaring
The share price of Provention Bio doubled yesterday after it released data which showed its immunotherapy PRV-031 (teplizumab) could delay the onset of of type 1 diabetes in children and ... Jeffrey Bluestone, a distinguished diabetes researcher and a
More from news
Approximately 5 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
The impact of COVID-19 on clinical trials
In one example, Provention Bio was forced to temporarily pause a phase 3 study evaluating its investigational therapy for type 1 diabetes.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
projects. Provention Bio. Provention Bio has appointed Jason Hoitt as its chief commercial officer. ... one diabetes (T1D) patients and at-risk individuals and, in parallel, advance our business development efforts for teplizumab,” said Ashleigh Palmer,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- The UK’s new medicines pricing deal – opportunities and risks for pharma
- Biogen’s Aduhelm unlikely to get approval in Europe
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
